MINNEAPOLIS--(BUSINESS WIRE)--MGI PHARMA, INC. (Nasdaq:MOGN), a biopharmaceutical company focused in oncology and acute care, announced the publication in the journal Blood of a phase 2 study that evaluated three schedules of low dose regimens for Dacogen™ (decitabine) for Injection in patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Interim results of this study were previously presented at the American Society of Hematology (ASH) Annual Meeting in 2005. The objective response rate (ORR) was 73 percent, including a 34 percent complete response (CR) rate, 1 percent partial response (PR) rate, 24 percent marrow CR rate with or without other hematologic improvement (HI) responses, and a 14 percent HI rate. Among the three regimens evaluated in this study, the CR rate was highest (39 percent) for patients treated with the five day intravenous infusion schedule. These results demonstrate the activity of Dacogen in patients with MDS and indicate that alternative dosing regimens may offer dose scheduling flexibility.
